GioTag
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 8, 2018 Category: Research Source Type: news

New Partnership to Develop Gene Therapy for Cystic Fibrosis
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 6, 2018 Category: Research Source Type: news

Boehringer Ingelheim launches the initiative InReachAfrica
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2018 Category: Research Source Type: news

H1
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2018 Category: Research Source Type: news

CARMELINA high level
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 16, 2018 Category: Research Source Type: news

New production center for Veterinary Public Health
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 10, 2018 Category: Research Source Type: news

Biologicals_fill_finish_Shanghai
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 3, 2018 Category: Research Source Type: news

CHMP Positive Opinion
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2018 Category: Research Source Type: news

World_Scleroderma_Day_2018
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2018 Category: Research Source Type: news

Atrial Fibrillation Poll
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 26, 2018 Category: Research Source Type: news

Type 1 Diabetes
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 25, 2018 Category: Research Source Type: news

New Biologicals Development Center in Germany announced
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 21, 2018 Category: Research Source Type: news

European Metacam ® indication expanded to guinea pigs
European Metacam ® indication expanded to guinea pigs (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 18, 2018 Category: Research Source Type: news

realgido study results
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 30, 2018 Category: Research Source Type: news

Spiolto Respimat enables greater physical activity
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 22, 2018 Category: Research Source Type: news

efficacy_and_safety_of_OFEV ®_ATS_2018
efficacy_and_safety_of_OFEV ®_ATS_2018 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 17, 2018 Category: Research Source Type: news

Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 16, 2018 Category: Research Source Type: news

Inauguration of new integrated Asian Veterinary R & D Center in China
Inauguration of new integrated Asian Veterinary R&D Center in China (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 15, 2018 Category: Research Source Type: news

annualpressconference
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 25, 2018 Category: Research Source Type: news

Transcending disease boundaries
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 25, 2018 Category: Research Source Type: news

Empa-kidney
EMPA-KIDNEY (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2018 Category: Research Source Type: news

Investment of 65 million euro in avian vaccines in France
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2018 Category: Research Source Type: news

New Partnership to develop novel checkpoint inhibitor
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 4, 2018 Category: Research Source Type: news

Results from landmark DYNAGITO trial
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 28, 2018 Category: Research Source Type: news

Boehringer Ingelheim announces 2018 BVDzero Case Awards
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 28, 2018 Category: Research Source Type: news

Joint Venture Targeting Foot-and-Mouth Disease in China
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 26, 2018 Category: Research Source Type: news

EHRA Congress 2018
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2018 Category: Research Source Type: news

FDA_Fast_Track_Designation
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 19, 2018 Category: Research Source Type: news

Expanded asthma indication for SPIRIVA RESPIMAT in EU
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 16, 2018 Category: Research Source Type: news

Expansion of Cancer Research with Vanderbilt University
Expansion of Cancer Research with Vanderbilt University (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 13, 2018 Category: Research Source Type: news

EMPERIAL heart failure
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 5, 2018 Category: Research Source Type: news

IPFwhywait
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 28, 2018 Category: Research Source Type: news

PRRS Research Award open for submissions until July 1st
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 20, 2018 Category: Research Source Type: news

Systemic Sclerosis World Congress
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 14, 2018 Category: Research Source Type: news

PDE9 Inhibition in AD
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 9, 2018 Category: Research Source Type: news

2018 Ruminant Well-Being Awards open for application
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 15, 2018 Category: Research Source Type: news

BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 9, 2018 Category: Research Source Type: news

BIVF funding more than doubled to 250 M €
BIVF funding more than doubled to 250 M € (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2018 Category: Research Source Type: news

Collaboration with Roche in Immunology
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 19, 2017 Category: Research Source Type: news

Collaboration with Autifony in CNS
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 18, 2017 Category: Research Source Type: news

Change in board of managing directors
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 15, 2017 Category: Research Source Type: news

GiotagStudy
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 12, 2017 Category: Research Source Type: news

Progress in immuno-oncology partnerships in 2017
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 11, 2017 Category: Research Source Type: news

Publication notice for the contribution of its Animal Health Business of Boehringer Ingelheim France SAS to Merial SAS
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 1, 2017 Category: Research Source Type: news

Safety and efficacy of Pradaxa ® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement
Safety and efficacy of Pradaxa ® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX ® during pregnancy and lactation in sows
European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX ® during pregnancy and lactation in sows (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto ® Respimat®
CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto ® Respimat® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data demonstrate sustained long-term efficacy of OFEV ®* on slowing disease progression and safety in patients with IPF
New data demonstrate sustained long-term efficacy of OFEV ®* on slowing disease progression and safety in patients with IPF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Jardiance ® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial
Jardiance ® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news